Investment
Features
FeesSafety
Academy
More
Pluang+

Accel Entertainment remains a Buy with 20-28% upside despite Chicago rollout delays.

Analyst Insights
19 Oct 2026
Seeking Alpha
View Source
Bullish
Accel Entertainment remains a Buy with 20-28% upside despite Chicago rollout delays.

Accel Entertainment is still rated a Buy with a short-term price target of $13–$14, representing a 20%–28% potential gain, and a longer-term target of $16 after its Chicago video gaming terminal (VGT) rollout. Although regulatory delays have slowed the Chicago launch, Accel's state license approvals suggest it could capture about 43.5% market share once operational. The company's core business maintains stable earnings through long-term VGT contracts, and regional acquisitions like Toucan Gaming contribute to growth. Current valuation multiples are attractive due to regulatory uncertainties, offering value even without Chicago revenue.

Accel Entertainment's recent update provides context for readers interested in consumer cyclical stocks. For readers following this sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 134 priced US stocks, 53 rose and 80 fell. Notable movers include Capri Holdings Ltd (CPRI) at USD 15.87 with a 1-day change of +5.66%, Abercrombie & Fitch Co. (ANF) at USD 161.94 also up +5.66%, and Best Buy Co Inc (BBY) at USD 93.99 with a +5.49% change.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App